During the international AIDS conference in Durban last July, complementary results were released on the effectivity studies of a vaginal ring that protects against HIV infection. The ring was developed by the International Partnership for Microbicides and contains the anti-retroviral drug Dapivirine.
The drug was developed by a Belgian biotech firm, which granted IPM a free licence for the development and production of the ring.
Effective when used consistently
Earlier this year, IPM announced that women using the ring during the effectivity studies were 27% and 31% less likely to contract HIV than women who did not use the ring. Complementary analyses now show that the ring is far more effective in women who use it consistently, they were 75% less likely to contract HIV compared to women who did not use the ring. The vaginal ring is the first long-acting form of HIV-prevention for women they can apply themselves.
More information about IPM
Effective when used consistently
Earlier this year, IPM announced that women using the ring during the effectivity studies were 27% and 31% less likely to contract HIV than women who did not use the ring. Complementary analyses now show that the ring is far more effective in women who use it consistently, they were 75% less likely to contract HIV compared to women who did not use the ring. The vaginal ring is the first long-acting form of HIV-prevention for women they can apply themselves.
More information about IPM
RSS Feed